C12Y 207/02007
Butyrate kinase
Official title: Butyrate kinase (2.7.2.7)
C12Y207/02007 (Butyrate kinase) appears on 17 US grants and 39 published applications in this corpus.
Search patents in C12Y- Granted patents
- 17
- Published applications
- 39
- Assignees
- 16
- Inventors
- 71
- Latest grant
- 16 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 3 |
| 2016 | 1 | 1 |
| 2017 | 2 | 6 |
| 2018 | 1 | 5 |
| 2019 | 3 | 3 |
| 2020 | 1 | 3 |
| 2021 | 3 | 5 |
| 2022 | 1 | 3 |
| 2023 | 2 | 2 |
| 2024 | 1 | 1 |
| 2025 | 2 | 2 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Means and methods for producing isobutene from acetyl-CoA16 Dec 2025US 12,497,635 B2
- Methods and compositions for treatment of microbiome associated disorders25 Feb 2025US 12,233,095 B2Pendulum Therapeutics, Inc.
- Fermentative production of B-ketoadipate from gaseous substrates5 Nov 2024US 12,134,794 B2LanzaTech, Inc.
- Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier27 Jun 2023US 11,685,925 B2Synlogic Operating Company, Inc.
- Methods and compositions for treatment of microbiome-associated disorders21 Feb 2023US 11,583,558 B2Pendulum Therapeutics, Inc.
- Methods for producing isobutene from 3-methylcrotonic acid23 Jul 2026US 2026/0209804 A1Global Bioenergies
- Microorganisms and methods for the continuous production of fatty acid derived products through the expression of 3-hydroxyacyl-acp:coa transacylases15 Jan 2026US 2026/0015572 A1LanzaTech, Inc.
- Organisms producing less crotonic acid23 Oct 2025US 2025/0327097 A1Global Bioenergies
- Engineered probiotics and the applications thereof22 May 2025US 2025/0161372 A1City University of Hong Kong
- Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier4 Apr 2024US 2024/0110192 A1Synlogic Operating Company, Inc.
Most cited
By later US patents
- Genetically engineered bacterium comprising energy-generating fermentation pathway17US 9,738,875 B2Lanzatech New Zealand Limited · 2017
- Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier12US 10,273,489 B2Synlogic Operating Company, Inc. · 2019
- Microorganisms and methods for production of specific length fatty alcohols and related compounds3US 10,513,716 B2Genomatica, Inc. · 2019
- Methods and compositions for treatment of microbiome-associated disorders3US 11,583,558 B2Pendulum Therapeutics, Inc. · 2023
- Genetically engineered bacterium for the production of isobutylene1US 10,316,337 B2Lanzatech New Zealand Limited · 2019